🚨2022 Küresel Kanser Raporu Alarm Veriyor!

1⃣Yüksek Hastalık Yükü: 2022 yılında dünya genelinde yaklaşık 20 milyon yeni kanser vakası ve 9.7 milyon kanser kaynaklı ölüm tahmin edildi. Bu, her beş erkekten birinin ve her dokuz erkekten birinin kanserden öldüğü anlamına

🚨 2022 Global Cancer Report Raises Alarm!

1⃣ High Disease Burden: In 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were estimated globally. This implies that one in five men and one in nine men will die from cancer.

2⃣ Most Common Cancer

Bilim tarihinde, en çok hayat kurtaran gelişmelerin başında aşıların keşfi geliyor!
Mesude Demir Diken

How effective is whole-pelvic radiation therapy (WPRT) in younger men with unfavorable-risk prostate cancer?
☢️ A new study shows WPRT significantly lowers the risk of death in men under 65. More long-term data is needed.
((A) younger than age 65 years and (B) 65 years or older)

FDA approves tisotumab vedotin-tftv for recurrent/metastatic cervical cancer.
🔘Major trial shows median OS of 11.5 months vs 9.5 with chemotherapy, PFS at 4.2 vs 2.9 months. ORR is 17.8% vs 5.2%.
🔘Watch for neuropathy & low hemoglobin.
🔘Don't forget, HPV vaccine is key

🎉 Huge congratulations to the team for hard work and dedication!
Brilliant job Coskun YAZGAN Erman Akkus Emre Yekedüz !
OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation Ankara Üniversitesi Ankara Üniversitesi Tıp Fakültesi
sciencedirect.com/science/articl…

Thanks Yüksel, was wonderful to have you with us!

Road to Zurich!

Can we use PET for de-escalation of treatment?
New study shows promising results in using PET scans to guide de-escalation of treatment in HER2-positive early breast cancer patients. PHERGain trial finds high 3-year invasive disease-free survival rates, suggesting some may safely

🩸New ASH guidelines on VTE in cancer patients: Strongly recommend LMWH for initial VTE treatment. Thromboprophylaxis advised for high-risk cases but not for low-risk chemotherapy patients.
#VTE #CancerCare #ASH
Alok Khorana, MD Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 Cihan Ay ASH Blood Advances

Phase 1 study of ARO-HIF2 shows promise in targeting HIF2α for ccRCC treatment, achieving tumor growth inhibition in a subset of patients. Challenges include neurotoxicity & low response rate.
James Brugarolas Clinical Cancer Research OncoAlert #Cancer #oncology Katy Beckermann Brian Rini, MD

In the case of asymptomatic patients with PSMA imaging-positive mCRPC, who are fit for chemotherapy, have received one line of ARPI and no chemotherapy, and for whom there is no actionable molecular alteration, the predominant choice (70% votes) is for 177Lu-PSMA therapy, which

For chemotherapy-fit patients with PSMA imaging-positive mCRPC who have already received one line of ARPI and one line of taxane-based chemotherapy, there is a strong consensus (96% of votes) favoring the use of 177Lu-PSMA therapy when no actionable molecular alteration is

No consensus!

When evaluating patients for 177Lu-PSMA therapy eligibility, the most commonly recommended imaging is PSMA PET and FDG PET selectively for equivocal cases, as 43% of respondents chose this option. Meanwhile, 33% recommend PSMA PET and bone scintigraphy, and 24%

The majority, at 70%, recommend imaging for response monitoring during 177Lu-PSMA treatment in the absence of clinical progression in most patients, indicating a consensus that regular imaging is crucial for effective treatment!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

In patients showing a response to 177Lu-PSMA therapy after 4 cycles, there's a consensus (76% agreement) for continuing to complete the 6 cycles if significant remaining uptake is noted. Conversely, if there’s no remaining uptake, most votes lean towards not continuing (57%

For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano

Who should receive chemotherapy before PSMA radioligand therapy?
Clinically very relevant question!
M.R.Smith

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen Emre Yekedüz Irbaz Riaz MD,MS,MBI,PhD Deborah Mukherji

How to utilize presence or absence of CT findings on a PSMA PET/CT
Fantastic talk by prof. Stefano Fanti
☢️ 'WITH GREAT POWER COMES GREAT RESPONSIBILITY.'
#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano Simon C Nick James GU Cast | Urology podcast! LARVOL Renu Eapen